BTK

Across TCGA pan-cancer cohorts, BTK mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of BTK’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where BTK mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BTK is over-expressed in tumor, although a few such as COAD and LUAD show the opposite, repressed pattern.

CCRCC, COAD, and LUAD are the cancer types where BTK tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BTK mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+1.141	<.001	12	view →
COAD	Female	II,III,IV	−0.697	<.001	9	view →
LUAD	Male	II,III,IV	−0.291	<.001	8	view →
LSCC	Male	II,III,IV	−0.532	<.001	7	view →
PDAC	Female	All	+0.896	<.001	5	view →
HNSC	Male	All	+0.296	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

BTK–CCRCC

Open the CCRCC breakdown →